• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Association of complementary medicine, cancer treatment, survival

Bioengineer by Bioengineer
July 19, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bottom Line: The use of complementary medicine by patients with four common cancers (breast, prostate, lung or colorectal) was associated with refusal of conventional cancer treatment and with a greater risk of death, although the difference in survival may be alleviated by adherence to all recommended conventional cancer therapies.

Why The Research Is Interesting: Complementary medicine is intended to be used in addition to conventional cancer therapy. Patients use a wide variety of complementary medicine, which can include herbs and botanicals, vitamins and minerals, traditional Chinese medicine, specialized diets, homeopathy and naturopathy, to improve their quality of life and with the hope of prolonging it. This study used a large national database to examine the use of complementary medicine by patients and delays in, or refusal of, conventional cancer therapies

Who and When: From among 1.9 million patients in the National Cancer Database, 258 patients who used complementary medicine were compared with 1,032 who didn't; patients were diagnosed with nonmetastatic breast, prostate, lung or colorectal cancer between 2004 and 2013

What (Study Measures and Outcomes): Use of complementary medicine (defined as "other-unproven: cancer treatments administered by nonmedical personnel") in addition to at least one conventional cancer therapy, which was defined as surgery, radiotherapy, chemotherapy or hormone therapy (exposures); overall survival, adherence to treatment and patient characteristics (outcomes)

Study Design: This was an observational study. Researchers were not intervening for purposes of the study and cannot totally control for all the natural differences that could explain the study results.

Authors: Skyler B. Johnson M.D., and James B. Yu, M.D., M.H.S., and coauthors at the Yale School of Medicine, New Haven, Connecticut

Limitations: The use of complementary medicine by patients was likely understated because patients are often hesitant to report its use to their clinicians; other factors unaccounted for could have influenced survival; and there are inherent limitations in the study's design

###

To Learn More: The full study is available on the For The Media website.

(doi:10.1001/jamaoncol.2018.2487)

Editor's Note: The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Want to embed a link to this study in your story?: Links will be live at the embargo time http://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2018.2487

Media Contact

Anne Doerr
[email protected]

@JAMAOnc

Share13Tweet8Share2ShareShareShare2

Related Posts

Deep Learning Uncovers Tetrahydrocarbazoles as Potent Broad-Spectrum Antitumor Agents with Click-Activated Targeted Cancer Therapy Approach

February 7, 2026

Newly Discovered Limonoid DHL-11 from Munronia henryi Targets IMPDH2 to Combat Triple-Negative Breast Cancer

February 7, 2026

New Discovery Reveals Why Ovarian Cancer Spreads Rapidly in the Abdomen

February 6, 2026

New Study Finds Americans Favor In-Clinic Screening Over At-Home Tests for Cervical Cancer

February 6, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Personalized Guide to Understanding and Reducing Chemicals

Inflammasome Protein ASC Drives Pancreatic Cancer Metabolism

Phage-Antibiotic Combo Beats Resistant Peritoneal Infection

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.